ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies announced today that they have been honored for their Targeted Radionuclide Therapy at the German Medical Award 2019 in the category “Medical Innovation Product”. The focus this year was placed on "Medicine of the Future". ITM received the award in recognition of their contribution to the improvement of outcomes and quality of life of cancer patients and its continued research in the development of innovative radiopharmaceuticals.
The German Medical Award accolades medical professionals, clinics and companies from the healthcare industry for their dedication and commitment to advanced patient care. The prize rewards the advocacy of medical ethics and the highest claim for quality standards. The German Medical Award committee, who determine the winner, consists of renowned physicians from various disciplines, researchers from science and practice but also medical quality managers, business administrators and lawyers with high expertise in the medical and healthcare industry.
The award-winning treatment approach, ITM's targeted radionuclide therapy, uses very small amounts of radioactive compounds called radiopharmaceuticals to diagnose and treat diseases, like cancer. Targeted radiopharmaceuticals contain a targeting molecule (e.g. peptide or antibody) and a medical radioactive isotope. The technique works by injecting the radio-conjugate into the patient’s body where it accumulates in the affected organs or lesions. The targeting molecule binds to a tumor- specific receptor or antigen, according to a lock and key principle.
In many cases, the targeting molecule can be used for both diagnosis and therapy – only the radioisotope is exchanged. For diagnostic purposes, radioisotopes with short half-lives such as Gallium-68 are used. Radioisotopes with longer half-lives are applied for treatment, such as ITM's high-purity no-carrier-added (n.c.a.) Lutetium-177 (EndolucinBeta®).The highly precise localization of the radioactivity ensures that healthy tissue surrounding the targeted tumor is minimally affected. Due to its extraordinary level of radionuclidic purity, there is no need for the logistics and storage of contaminated radioactive waste for clinics.
Steffen Schuster, CEO of ITM, commented: "We are very proud and grateful to receive the German Medical Award for our Targeted Radionuclide Therapy. The focus of this award lies with patient benefit which is a great honor for us. Our work at ITM is very patient focused: each and every one of our employees is aware that their efforts contribute towards improving the treatment and quality of life of cancer patients. I would like to thank the jury and our partners, but first and foremost our team who work together every day to further develop our therapy and without whose commitment this success would not be possible."
- Ends -
About the German Medical Award
The German Medical Award has, for several years now, been awarded by the German Medical Club e.V. The German Medical Award is the leading medical and management award honoring clinics, general practitioners, researchers and healthcare professionals for their outstanding and progressive patient care. The award has earned a high reputation among professionals in medicine, research and healthcare and is considered to be an important award for innovation, transparency and quality in medicine. The focus is placed on interdisciplinary, medical, technical, and pharmaceutical care solutions as well as on patient-oriented clinical management and the use of modern communication techniques. Further information about the German Medical Award is available at: www.germanmedicalaward.com
About ITM Isotopen Technologien München
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radionuclides and generator platforms for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors and bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information about ITM, please visit: www.itm.ag
Head of Marketing
Phone: +49 89 3298986-151
Press Contact: WE Communications
Phone: +49 89 628175-46